As the 37th annual San Antonio Breast Cancer Symposium (SABCS) drew to a close, a range of intriguing clinical observations and long-awaited trial updates had made the event a valuable experience for investigators and attendees alike. Among some of the most interesting updates, in my opinion, were advancements in treatments for estrogen receptor-positive (ER-positive) breast cancer, premenopausal breast cancers and advanced breast cancers.
ER Positive Breast Cancers
Results from the FERGI trial were presented at this year’s meeting. This trial is investigating the new agent pictilisib, which belong to a new class of drugs called PI3K inhibitors that […]